Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,409 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06577961 | Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients | not yet recruiting | Phase 1 / Phase 2 | 37 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06574412 | Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma. | not yet recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 0 | Aug 28, 2024 |
| clinicaltrials |
| NCT06572501 | Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral Position | recruiting | N/A | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT04498767 | Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)(OligoRARE) | recruiting | N/A | 200 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Aug 26, 2024 | clinicaltrials |
| NCT06523049 | Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy | not yet recruiting | Phase 2 | 67 | Hao ZengOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06469229 | Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria | not yet recruiting | — | 1,200 | Changhai HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05215470 | CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy | active not recruiting | Phase 2 | 100 | Hospital das Clínicas de Ribeirão PretoOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06472752 | Neoadjuvant Radiotherapy for High-risk UTUC(LUXUS07) | not yet recruiting | — | 40 | Peking University First HospitalOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06472895 | A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 25, 2024 | clinicaltrials |
| NCT06467097 | Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma(SABLOR) | recruiting | Phase 3 | 88 | Samsung Medical CenterOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT02293980 | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | active not recruiting | Phase 1 | 110 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06441851 | Study to Compare Two Partial Nephrectomy Techniques for Renal Tumors: Robot-assisted vs Videolaparoscopic(VPN x RANP) | not yet recruiting | N/A | 50 | Instituto do Cancer do Estado de São PauloOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06399419 | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | recruiting | Phase 1 | 28 | Osel, Inc.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT05817604 | Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)(SABINA) | active not recruiting | — | 60 | Consorci Sanitari de TerrassaOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05539677 | Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research(REGATA) | recruiting | — | 1,000 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05868174 | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | recruiting | Phase 1 | 36 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT03749980 | MyVHL: Patient Natural History Study(MyVHL) | recruiting | — | 10,000 | Joshua Mann, MPHOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06383507 | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 18 | Zhejiang UniversityOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT06354231 | DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06336187 | European Active Surveillance of Renal Cell Carcinoma Study (EASE RCC Study)(EASE) | recruiting | — | 400 | Azienda Ospedaliero Universitaria Maggiore della CaritaOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06278506 | Resection or Ablation of Small Kidney Tumors(RESTART) | recruiting | N/A | 300 | Karolinska University HospitalOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06041555 | MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)(ISRAR) | recruiting | — | 600 | Hospices Civils de LyonOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05731622 | Effect of a SI-MMC on the IVR Rate After Ureteroscopy for UTUC(SINCERE) | recruiting | — | 100 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT03414827 | Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma | recruiting | — | 120 | Zealand University HospitalOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03857373 | Renal Cancer Detection Using Convolutional Neural Networks(RCCCNN) | recruiting | — | 5,000 | Nessn AzawiOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06211790 | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06194669 | Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells(SoMuKT) | recruiting | — | 50 | IRCCS San RaffaeleOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06169436 | Translational Cancer Observational Protocol | recruiting | — | 1,250 | IRCCS San RaffaeleOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06146777 | Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy | not yet recruiting | Phase 3 | 468 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Nov 29, 2023 | clinicaltrials |
| NCT06147349 | Kidney Cancer Observational Protocol | recruiting | — | 2,500 | IRCCS San RaffaeleOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06145139 | KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial(KIDNEY-PAGER) | enrolling by invitation | — | 500 | University of AarhusOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06010875 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05899361 | A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest | recruiting | N/A | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT06093568 | Delving Into Participation Trends in Renal Cell Carcinoma Studies | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06032728 | Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment | not yet recruiting | N/A | 488 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT03501381 | High Dose IL 2 and Entinostat in RCC | active not recruiting | Phase 2 | 46 | Roberto PiliOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05941169 | Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy(PrimerX) | not yet recruiting | N/A | 750 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 0 | Jul 12, 2023 | clinicaltrials |
| NCT05753839 | The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial(SEVURO-CN) | recruiting | N/A | 40 | Yonsei UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05817903 | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients(AxIn) | recruiting | Phase 2 | 118 | Consorzio OncotechOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT05810623 | Single-Dose Intravesical Chemotherapy After Diagnostic URS(MINERVA) | not yet recruiting | Phase 3 | 394 | David D'AndreaOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05589207 | Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion | recruiting | — | 232 | Peking University Third HospitalOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04625556 | Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome | recruiting | — | 3,000 | Yonsei UniversityOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05218811 | Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach(RCAPN) | recruiting | N/A | 150 | Urological Research Network, LLCOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05241561 | Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients(Cabo-POLARIS) | not yet recruiting | Phase 2 | 24 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05363657 | International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors(i-RECORd) | recruiting | — | 10,000 | Azienda Ospedaliero-Universitaria CareggiOTHER | 13 | May 6, 2022 | clinicaltrials |
| NCT05037825 | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors(PARADIGM) | recruiting | — | 800 | VastBiomeINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05214885 | Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma | recruiting | — | 300 | Qianfoshan HospitalOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03308396 | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | Ajjai Alva, MDOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT04712305 | Urine Omics Predicting IO Therapy Responses in mRCC Patients | recruiting | — | 400 | National Taiwan University HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Aug 29, 2024source: clinicaltrials